Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer, HER2 Negative Primary Tumor
Interventions: DRUG: Trastuzumab - Emtansine
Sponsor: Institut Curie